Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Recent & Breaking News (NDAQ:MRKR)

U.S. Food & Drug Administration Grants Orphan Drug Designation to TapImmune's TPIV 200 in the Treatment of Ovarian Cancer

PR Newswire December 9, 2015

TapImmune to Present New Data at San Antonio Breast Cancer Symposium on December 10, 2015

PR Newswire December 7, 2015

TapImmune to Present at LD Micro Main Event on December 1, 2015

PR Newswire November 30, 2015

Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters to Jacksonville Florida

PR Newswire November 5, 2015

Latest Updates in Diverse Sectors Equities - Research on Agora Holdings, Rocky Mountain High Brands, TapImmune and MyEcheck

Accesswire October 28, 2015

TapImmune to Present at Dawson James Small Cap Growth Conference in Florida on October 15, 2015

PR Newswire October 13, 2015

TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015

PR Newswire October 7, 2015

Investors Exhibiting Increased Interest In Small Cap Stocks, Including CD International (CDII) And More

Accesswire October 1, 2015

SeeThruEquity Issues Company Update on TapImmune Highlighting Clinical Program Updates and Recent Financing

Accesswire September 28, 2015

SeeThruEquity Issues Company Update on TapImmune Highlighting Clinical Program Updates and Recent Financing

Accesswire September 28, 2015

TapImmune Vaccine to be Studied in a $13.3 Million U.S. Department of Defense Grant to Mayo Clinic for Phase II Clinical Trial in Triple Negative Breast Cancer

PR Newswire September 15, 2015

TapImmune To Provide Update On and Confirmation Of Phase II Clinic Trial Initiation

PR Newswire September 10, 2015

TapImmune Inc to Present at the SeeThruEquities Fall

PR Newswire September 8, 2015

TapImmune Inc. to Present at 17th Annual Rodman & Renshaw Healthcare Conference

PR Newswire September 2, 2015

At the Forefront of Immunology: WSA Interviews Immune Pharma and TapImmune

Marketwired August 19, 2015

TapImmune Completes Transfer of IND From The Mayo Clinic

PR Newswire August 18, 2015

TapImmune Appoints John N. Bonfiglio, Ph.D., to its Board of Directors

PR Newswire July 30, 2015

TapImmune Announces Finalization of License Agreement With Mayo Clinic To Commercialize a Folate Receptor Alpha Vaccine for Multiple Cancer Indications

PR Newswire July 27, 2015

The Wealthy Biotech Trader's New Feature Pick Runs Over 150% After Announcement - Traders are Calling it the Next PPCH 3,200%+ Runner

Accesswire June 25, 2015

TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients

PR Newswire June 23, 2015